These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23820406)

  • 1. Authors' response.
    Turner D; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25-6. PubMed ID: 23820406
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease.
    Furuta GT; Atkins D; Capocelli KE; de Zoeten EF; Fleischer D; Menard-Katcher C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25. PubMed ID: 23820407
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease.
    Turner D; Wolters VM; Russell RK; Shakhnovich V; Muise AM; Ledder O; Ngan B; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 May; 56(5):492-7. PubMed ID: 23221994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
    Licinio R; Losurdo G; Ierardi E; Di Leo A; Principi M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302. PubMed ID: 25968153
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
    Macaluso FS; Criscuoli V; Orlando E; Rizzuto G; Renna S; Cottone M; Orlando A
    Aliment Pharmacol Ther; 2016 May; 43(9):1019-20. PubMed ID: 27040168
    [No Abstract]   [Full Text] [Related]  

  • 8. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
    Kane S
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H; Lipka S; Katz S
    J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic review suggests TNF-α inhibitors may be rational options for pregnant patients with inflammatory bowel disease.
    Levesque BG; Pountney-Levesque ME
    Evid Based Med; 2014 Apr; 19(2):e15. PubMed ID: 24282175
    [No Abstract]   [Full Text] [Related]  

  • 12. Biologic therapy in inflammatory bowel disease.
    Loftus EV
    Gastroenterol Clin North Am; 2014 Sep; 43(3):xv-xvii. PubMed ID: 25110264
    [No Abstract]   [Full Text] [Related]  

  • 13. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
    El Shabrawi-Caelen L; La Placa M; Vincenzi C; Haidn T; Muellegger R; Tosti A
    Inflamm Bowel Dis; 2010 Feb; 16(2):182-3. PubMed ID: 19462433
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Coskun M; Nielsen OH
    N Engl J Med; 2013 Dec; 369(26):2561-2. PubMed ID: 24369082
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Peyrin-Biroulet L
    N Engl J Med; 2013 Dec; 369(26):2561. PubMed ID: 24369083
    [No Abstract]   [Full Text] [Related]  

  • 16. [Managing inflammatory bowel disease in the biologics era: treating beyond symptoms is not sufficient].
    Peyrin-Biroulet L
    Rev Prat; 2014 Nov; 64(9):1207-9. PubMed ID: 25638855
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
    Salgueiro P; Lago P; Pedroto I
    J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
    [No Abstract]   [Full Text] [Related]  

  • 19. [Commentaries on the article "are there frequent errors in the management of outpatients with inflammatory bowel disease?"].
    Sánchez-Muñoz D; Castro-Fernández M
    Gastroenterol Hepatol; 2008 Apr; 31(4):265. PubMed ID: 18405494
    [No Abstract]   [Full Text] [Related]  

  • 20. Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?
    Dreesen E; Gils A
    J Crohns Colitis; 2017 Aug; 11(8):903-904. PubMed ID: 28333273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.